Private Equity

Updated:

Biossom Investment Management

Biossom Investment Management is a venture capital fund focused on bio-pharmaceuticals investments. It has made 12 investments, including a Series A - II...

Biossom Investment Management

Biossom Investment Management is a venture capital fund focused on bio-pharmaceuticals investments. It has made 12 investments, including a Series A - II investment in Pharmcube on September 17, 2018. The firm has 5 portfolio exits, with Biostar being its most recent exit on October 31, 2024.

General information

Firm type

Private Equity

Year founded

2012

Location

Region

Asia

Country

China

City

Beijing

Corporate office

Beijing, China

Frequently asked questions

What investment stages does Biossom Investment Management target?

Biossom covers a full venture lifecycle: early-stage seed and startup rounds, plus expansion and late-stage growth capital. The firm categorizes this as generalist venture, meaning it does not restrict itself to a single-point entry and can follow portfolio companies through multiple funding rounds. This multi-stage approach is documented in the firm's own strategy disclosures.

Where is Biossom Investment Management's geographic focus?

The firm is headquartered in Beijing and concentrates its investment activity within China. No additional offices or cross-border mandates have been identified in public record. The single-jurisdiction focus aligns with the deep-local sourcing required for competitive early-stage venture in the Chinese market.

What is Biossom's known posture on co-investments alongside external GPs?

Public record does not detail Biossom's co-investment practices. For a venture-stage firm of its profile in Beijing, co-investment typically depends on deal-by-deal syndicate formation rather than a formalized separate co-investment vehicle. No public syndication records or GP-relationship disclosures are available to confirm active practice.

How does Biossom Investment Management source its deal flow?

The firm's absence of a public website or LinkedIn presence suggests relationship-based sourcing rather than a broad institutional marketing approach. In China's venture ecosystem, this often means direct founder networks, university pipelines, and referrals from portfolio company executives—though specific sourcing channels are not publicly disclosed by the firm.

Is Biossom structured as a family office or a traditional venture firm?

Biossom is categorized as an asset manager operating a private equity strategy, not a single-family office. The firm's multi-stage venture mandate and Beijing headquarters suggest a pooled-capital vehicle rather than a dedicated family wealth manager. No public information confirms the identity of any single family or patronage structure.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Beijing Private Equity profiles